Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Basilea Pharmaceutica clinical trials
The registry lists 59 studies whose lead sponsor is Basilea Pharmaceutica. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Basilea Pharmaceutica studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Basilea Pharmaceutica.
- Basilea Pharmaceutica59 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 59. Browse all 59 →
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.RecruitingNCT05421858Phase 3
- A Multiple-dose Study Investigating the Drug-drug Interaction Potential and QTc Effects of Fosmanogepix in Healthy Adult SubjectsRecruitingNCT07881224Phase 1
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.RecruitingNCT06925321Phase 3
- A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BAL2420 in Healthy Adult SubjectsRecruitingNCT07500181Phase 1
- Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose CombinationRecruitingNCT06733675Phase 1
- Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal InfectionsAvailableNCT06433128
- Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus BacteremiaCompletedNCT03138733Phase 3
- Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure InfectionsCompletedNCT03137173Phase 3
- Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adults (18-55 Years)CompletedNCT06665555Phase 1
- A Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of CoproporphyrinCompletedNCT06808646Phase 1
- A Study of Fosmanogepix in Healthy Adult Chinese SubjectsCompletedNCT06961708Phase 1
- A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.CompletedNCT05582187Phase 1
- Food Effect on Ceftibuten/VNRX-7145 in Healthy ParticipantsCompletedNCT05527834Phase 1
- VNRX-7145 Drug-Drug Interaction in Healthy Adult VolunteersCompletedNCT04877379Phase 1
- Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal FunctionCompletedNCT05488678Phase 1
- VNRX-7145 SAD/MAD Safety and PK in Healthy Adult VolunteersCompletedNCT04243863Phase 1
- VNRX-5024 Safety and PK in Healthy Adult VolunteersCompletedNCT04314206Phase 1
- Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare MoldsTerminatedNCT04240886Phase 2
- An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida AurisCompletedNCT04148287Phase 2
- An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With CandidemiaCompletedNCT03604705Phase 2
- Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered OrallyCompletedNCT02957929Phase 1
- Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy SubjectsCompletedNCT02956499Phase 1
- Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of AgeCompletedNCT05856227Phase 3
- Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic AlterationsNo longer availableNCT04087876
- A Bioequivalence Study of APX001 High-load and Low-load TabletsCompletedNCT05491733Phase 1
- Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade GliomaCompletedNCT02490800Phase 1/2
- Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaTerminatedNCT03250299Phase 1
- A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001CompletedNCT04166669Phase 1
- A Study to Assess the Mass Balance Recovery and Metabolite Profile & Identification of [14C]-APX001 in Healthy MalesCompletedNCT04804059Phase 1
- Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and NeutropeniaCompletedNCT03333005Phase 1
- Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric AdenocarcinomaTerminatedNCT04604132Phase 1/2
- Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic CholangiocarcinomaCompletedNCT03230318Phase 2
- Derazantinib and Atezolizumab in Patients With Urothelial CancerCompletedNCT04045613Phase 1/2
- Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsCompletedNCT01752920Phase 1/2
- Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic AntibioticsTerminatedNCT02527681Phase 1
- Ceftobiprole in the Treatment of Pediatric Patients With PneumoniaCompletedNCT03439124Phase 3
- An Open-Label Study of Intravenous BAL101553 in Adult Patients With Solid TumorsCompletedNCT01397929Phase 1/2
- Phase 1/2a Study of BAL101553 as 48-hour Infusions in Patients With Advanced Solid Tumors or Recurrent GlioblastomaCompletedNCT02895360Phase 1/2
- Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing ChemotherapyCompletedNCT00413439Phase 2/3
- Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand DermatitisCompletedNCT00124436Phase 3
- Alitretinoin in the Treatment of Chronic Hand EczemaCompletedNCT00519675Phase 3
- Safety and Efficacy of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedNCT00309621Phase 3
- Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand DermatitisCompletedNCT00124475Phase 3
- Mass Balance and Pharmacokinetics Study of Derazantinib in Healthy Male SubjectsCompletedNCT04098692Phase 1
- Ceftobiprole in the Treatment of Hospitalized Patients With Staphylococcus Aureus BacteremiaWithdrawnNCT00505258Phase 2
- Ceftobiprole in Hospital Acquired PneumoniaCompletedNCT00210964Phase 3
- Ceftobiprole in Hospital Acquired PneumoniaCompletedNCT00229008Phase 3
- Pharmacokinetic Study,Ceftobiprole,Healthy Volunteers,Healthy Patients With End Stage Renal DiseaseCompletedNCT01030731Phase 1
- A Study Evaluating the Pharmacokinetics of Ceftobiprole When Taken by Obese PatientsCompletedNCT01026558Phase 1
- Ceftobiprole in the Treatment of Patients With Community-Acquired PneumoniaCompletedNCT00326287Phase 3